Please enable JavaScript to continue using this application.

Compare $DSGN vs $NVCT | Chartloom

Compare

$DSGN vs $NVCT

Design Therapeutics Inc · Nuvectis Pharma Inc

DSGN

Design Therapeutics Inc

NVCT

Nuvectis Pharma Inc

Compare $DSGN vs $NVCT

Comparing Design Therapeutics Inc and Nuvectis Pharma Inc

DSGNDesign Therapeutics Inc

NVCTNuvectis Pharma Inc

DSGNDesign Therapeutics Inc

Market cap

$728M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

28.0%

52W performance

67.9%

FCF yield

-7.6%

NVCTNuvectis Pharma Inc

Market cap

$666M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

148.2%

52W performance

239.0%

FCF yield

-2.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

DSGN

NVCT

Detailed metrics comparison

DSGN

Design Therapeutics Inc

NVCT

Nuvectis Pharma Inc

Market Cap

DSGN$728M

NVCT$666M

Enterprise Value

DSGN$715M

NVCT$644M

Price

DSGN$11.65

NVCT$21.12

P/E Ratio

DSGNN/A

NVCTN/A

P/S Ratio

DSGN0.00x

NVCT0.00x

EV/Sales

DSGN0.00x

NVCT0.00x

EV/EBITDA

DSGN0.00x

NVCT0.00x

P/B Ratio

DSGN3.83x

NVCT78.79x

P/FCF Ratio

DSGNN/A

NVCTN/A

EV/FCF

DSGN-12.96x

NVCT-33.00x

PEG Ratio

DSGNN/A

NVCTN/A

Forward P/E (NTM)

DSGNN/A

NVCTN/A

Forward P/S (NTM)

DSGNN/A

NVCTN/A

Revenue (TTM)

DSGN$0

NVCT$0

Revenue Growth (YoY)

DSGNN/A

NVCTN/A

Forward Rev Growth

DSGN1360.4%

NVCT0.0%

Gross Margin (TTM)

DSGN0.0%

NVCT0.0%

Operating Margin (TTM)

DSGN0.0%

NVCT0.0%

EBITDA Margin (TTM)

DSGN0.0%

NVCT0.0%

Net Margin (TTM)

DSGN0.0%

NVCT0.0%

FCF Margin (TTM)

DSGNN/A

NVCTN/A

Net Income (TTM)

DSGN$-71M

NVCT$-30M

FCF (TTM)

DSGN$-55M

NVCT$-20M

EPS (TTM)

DSGN-$1.13

NVCT-$1.29

ROE (TTM)

DSGN-3403.0%

NVCT-16947.0%

ROA (TTM)

DSGN-3205.0%

NVCT-9680.0%

ROIC (TTM)

DSGN-3403.0%

NVCT-16947.0%

Cash

DSGN$13M

NVCT$22M

Debt

DSGN$0

NVCT$0

Net Cash/Debt

DSGN$13M

NVCT$22M

Current Ratio (TTM)

DSGN18.86x

NVCT1.68x

Quick Ratio (TTM)

DSGN18.61x

NVCT1.68x

Debt/Equity (TTM)

DSGN0.00x

NVCT0.00x

Debt/Assets (TTM)

DSGN0.0%

NVCT0.0%

Interest Coverage (TTM)

DSGNN/A

NVCTN/A

Net Debt/EBITDA (TTM)

DSGN0.00x

NVCT0.00x

Beta

DSGN1.72

NVCT-0.23

52W Performance

DSGN67.9%

NVCT239.0%

YTD Performance

DSGN28.0%

NVCT148.2%

% from 52W High

DSGN-32.5%

NVCT-27.9%

% from 52W Low

DSGN120.6%

NVCT280.5%

Asset Turnover (TTM)

DSGN0.00x

NVCT0.00x

FCF Yield (TTM)

DSGN-7.6%

NVCT-2.9%

Earnings Yield (TTM)

DSGN-9.7%

NVCT-4.5%

Dividend Yield (TTM)

DSGNN/A

NVCTN/A

Rule of 40

DSGN0.0

NVCT0.0

EV/GP/RG

DSGNN/A

NVCTN/A

Ticker research

View DSGN research View NVCT research

Metric	DSGN Design Therapeutics Inc	NVCT Nuvectis Pharma Inc
Market & Valuation
Market Cap	$728M	$666M
Enterprise Value	$715M	$644M
Price	$11.65	$21.12
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.83x	78.79x
P/FCF Ratio	N/A	N/A
EV/FCF	-12.96x	-33.00x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	1360.4%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-71M	$-30M
FCF (TTM)	$-55M	$-20M
EPS (TTM)	-$1.13	-$1.29
ROE (TTM)	-3403.0%	-16947.0%
ROA (TTM)	-3205.0%	-9680.0%
ROIC (TTM)	-3403.0%	-16947.0%
Financial Health
Cash	$13M	$22M
Debt	$0	$0
Net Cash/Debt	$13M	$22M
Current Ratio (TTM)	18.86x	1.68x
Quick Ratio (TTM)	18.61x	1.68x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.72	-0.23
52W Performance	67.9%	239.0%
YTD Performance	28.0%	148.2%
% from 52W High	-32.5%	-27.9%
% from 52W Low	120.6%	280.5%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-7.6%	-2.9%
Earnings Yield (TTM)	-9.7%	-4.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View DSGN research	View NVCT research

Valuation

P/S Ratio

DSGN

0.00x

NVCT

0.00x

EV/FCF

NVCT

-33.00x

DSGN

-12.96x

Growth & revenue

Forward Revenue Growth

DSGN

1360.4%

NVCT

0.0%

Profitability & performance

Gross Margin

DSGN

0.0%

NVCT

0.0%

ROE

DSGN

-3403.0%

NVCT

-16947.0%

FCF Yield %

NVCT

-2.9%

DSGN

-7.6%

52-Week Performance

NVCT

239.0%

DSGN

67.9%

Detailed metrics comparison

DSGN

Design Therapeutics Inc

NVCT

Nuvectis Pharma Inc

Market Cap

DSGN$728M

NVCT$666M

Enterprise Value

DSGN$715M

NVCT$644M

Price

DSGN$11.65

NVCT$21.12

P/E Ratio

DSGNN/A

NVCTN/A

P/S Ratio

DSGN0.00x

NVCT0.00x

EV/Sales

DSGN0.00x

NVCT0.00x

EV/EBITDA

DSGN0.00x

NVCT0.00x

P/B Ratio

DSGN3.83x

NVCT78.79x

P/FCF Ratio

DSGNN/A

NVCTN/A

EV/FCF

DSGN-12.96x

NVCT-33.00x

PEG Ratio

DSGNN/A

NVCTN/A

Forward P/E (NTM)

DSGNN/A

NVCTN/A

Forward P/S (NTM)

DSGNN/A

NVCTN/A

Revenue (TTM)

DSGN$0

NVCT$0

Revenue Growth (YoY)

DSGNN/A

NVCTN/A

Forward Rev Growth

DSGN1360.4%

NVCT0.0%

Gross Margin (TTM)

DSGN0.0%

NVCT0.0%

Operating Margin (TTM)

DSGN0.0%

NVCT0.0%

EBITDA Margin (TTM)

DSGN0.0%

NVCT0.0%

Net Margin (TTM)

DSGN0.0%

NVCT0.0%

FCF Margin (TTM)

DSGNN/A

NVCTN/A

Net Income (TTM)

DSGN$-71M

NVCT$-30M

FCF (TTM)

DSGN$-55M

NVCT$-20M

EPS (TTM)

DSGN-$1.13

NVCT-$1.29

ROE (TTM)

DSGN-3403.0%

NVCT-16947.0%

ROA (TTM)

DSGN-3205.0%

NVCT-9680.0%

ROIC (TTM)

DSGN-3403.0%

NVCT-16947.0%

Cash

DSGN$13M

NVCT$22M

Debt

DSGN$0

NVCT$0

Net Cash/Debt

DSGN$13M

NVCT$22M

Current Ratio (TTM)

DSGN18.86x

NVCT1.68x

Quick Ratio (TTM)

DSGN18.61x

NVCT1.68x

Debt/Equity (TTM)

DSGN0.00x

NVCT0.00x

Debt/Assets (TTM)

DSGN0.0%

NVCT0.0%

Interest Coverage (TTM)

DSGNN/A

NVCTN/A

Net Debt/EBITDA (TTM)

DSGN0.00x

NVCT0.00x

Beta

DSGN1.72

NVCT-0.23

52W Performance

DSGN67.9%

NVCT239.0%

YTD Performance

DSGN28.0%

NVCT148.2%

% from 52W High

DSGN-32.5%

NVCT-27.9%

% from 52W Low

DSGN120.6%

NVCT280.5%

Asset Turnover (TTM)

DSGN0.00x

NVCT0.00x

FCF Yield (TTM)

DSGN-7.6%

NVCT-2.9%

Earnings Yield (TTM)

DSGN-9.7%

NVCT-4.5%

Dividend Yield (TTM)

DSGNN/A

NVCTN/A

Rule of 40

DSGN0.0

NVCT0.0

EV/GP/RG

DSGNN/A

NVCTN/A

Ticker research

View DSGN research View NVCT research

Metric	DSGN Design Therapeutics Inc	NVCT Nuvectis Pharma Inc
Market & Valuation
Market Cap	$728M	$666M
Enterprise Value	$715M	$644M
Price	$11.65	$21.12
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.83x	78.79x
P/FCF Ratio	N/A	N/A
EV/FCF	-12.96x	-33.00x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	1360.4%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-71M	$-30M
FCF (TTM)	$-55M	$-20M
EPS (TTM)	-$1.13	-$1.29
ROE (TTM)	-3403.0%	-16947.0%
ROA (TTM)	-3205.0%	-9680.0%
ROIC (TTM)	-3403.0%	-16947.0%
Financial Health
Cash	$13M	$22M
Debt	$0	$0
Net Cash/Debt	$13M	$22M
Current Ratio (TTM)	18.86x	1.68x
Quick Ratio (TTM)	18.61x	1.68x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.72	-0.23
52W Performance	67.9%	239.0%
YTD Performance	28.0%	148.2%
% from 52W High	-32.5%	-27.9%
% from 52W Low	120.6%	280.5%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-7.6%	-2.9%
Earnings Yield (TTM)	-9.7%	-4.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View DSGN research	View NVCT research